-transparent.png){kind=logo}
The therapeutic use of doxorubicin (an antitumoral antibiotic belonging to the anthracycline group) is limited by its cardiotoxicity. Adriamycin (DXR) causes myocardial subcellular damage, such as myocytolysis, disarray of actin filaments, and alterations in the Z-band with loss of sarcomeric organization. We studied the effect of stoichiometrical concentrations of DXR on the interaction between cardiac actin and alpha-actinin in solution. Doxorubicin inhibits the formation of alpha-actinin/actin tridimensional networks and bundles. The main effect of the drug seems to be on the size of the actin polymers.
Related Publications
I DalleDonne, and
A Milzani, and
P Contini, and
G Bernardini, and
R Colombo
January 1982,
Biofizika,
I DalleDonne, and
A Milzani, and
P Contini, and
G Bernardini, and
R Colombo
April 2000,
IUBMB life,
I DalleDonne, and
A Milzani, and
P Contini, and
G Bernardini, and
R Colombo
December 1979,
Biochimica et biophysica acta,
I DalleDonne, and
A Milzani, and
P Contini, and
G Bernardini, and
R Colombo
June 1992,
The Journal of cell biology,
I DalleDonne, and
A Milzani, and
P Contini, and
G Bernardini, and
R Colombo
February 1976,
The Journal of cell biology,
I DalleDonne, and
A Milzani, and
P Contini, and
G Bernardini, and
R Colombo
February 1994,
FEBS letters,
I DalleDonne, and
A Milzani, and
P Contini, and
G Bernardini, and
R Colombo
February 1995,
Biochemical Society transactions,
I DalleDonne, and
A Milzani, and
P Contini, and
G Bernardini, and
R Colombo
July 1968,
European journal of biochemistry,
I DalleDonne, and
A Milzani, and
P Contini, and
G Bernardini, and
R Colombo
April 1967,
Biochimica et biophysica acta,
I DalleDonne, and
A Milzani, and
P Contini, and
G Bernardini, and
R Colombo
November 1969,
Journal of biochemistry,
